Therapeutic options for patients with chronic liver diseases are presently far from satisfactory. Ursodeoxycholic acid, a naturally occurring dihydroxy bile acid, is increasingly being considered for the therapy ofa variety ofchronic liver diseases, especially chronic cholestatic liver diseases. Although the role ofursodeoxycholic acid in liver disease has been appreciated in the Western world only recently, it has been known and utilised in China for centuries. The early preparations were crude -the dried bile of the black bear called 'Yutan' which contains predominantly ursodeoxycholic acid.1 In Japan, ursodeoxycholic acid has been used since 1957 for a variety of gastrointestinal disorders and, indeed, the first two controlled trials of its use in chronic hepatitis came from there in 1976.2,3
The present review focuses on the pharmacology, indications and results of the use of ursodeoxycholic acid in various liver diseases. Bioavailability of ursodeoxycholic acid Ursodeoxycholic acid is a 7B epimer of chenodeoxycholic acid.4 Conversion of chenodeoxycholic acid into ursodeoxycholic acid occurs in two stages via 7-ketolithocholic acid. Ursodeoxycholic acid is a secondary bile acid (produced in the gut) as well as a tertiary bile acid (produced in the liver).5'6
About 30-60% of orally administered ursodeoxycholic acid is absorbed. 7 Although poorly water soluble in the protonated form, unconjugated ursodeoxycholic acid is absorbed along the entire length of the jejunum and ileum by non-ionic passive diffusion8; about 20% may be absorbed in the colon.9 The In three of these studies, the duration of treatnent was short and, following discontinuation, enzyme values returned to pretreatment levels within four weeks in the majority of patients. The mechanism of action of ursodeoxycholic acid in chronic hepatitis may be related to its membrane stabilising, choleretic or immunomodulatory action. The major limitation of this therapy is the lack of antiviral effect. A recent study from Germany has shown that ursodeoxycholic acid has no positive impact on HCV RNA titres or HCV IgM in patients with chronic hepatitis C and the major mechanism for improvement in liver enzymes is the choleretic effect of ursodeoxycholic acid. 65 An Italian study has shown that ursodeoxycholic acid might induce alanine transaminase normalisation in patients with chronic hepatitis C not responding to interferon treatment. 60 In autoimmune hepatitis type 1 ursodeoxycholic acid has been shown to induce a significant fall in IgG and y-globulins and an improvement in intrahepatic inflammation but not fibrosis. 67 In combination with vitamin K1, ursodeoxycholic acid has been shown to reduce the haemorrhagic tendency in patients with decompensated cirrhosis of the liver.68 On the basis of the existing data, however, no definite recommendation can be made for the dose, duration or efficacy of ursodeoxycholic acid in chronic hepatitis or liver cirrhosis.
INTRAHEPATIC CHOLESTASIS OF PREGNANCY
Ursodeoxycholic acid has been tried in an open-label trial in eight patients with cholestasis ofpregnancy.69 Significant improvement was reported in pruritus and serum alanine transaminase levels, No adverse effects were reported in the mother or child. All patients had received ursodeoxycholic acid in the second half of the pregnancy, ie, after organogenesis. Randomised double-blind trials are required before ursodeoxycholic acid can be considered as a therapeutic option for intrahepatic cholestasis of pregnancy. Amniotic fluid and umbilical cord bile acid content in patients with intrahepatic cholestasis of pregnancy may pose a threat to foetal well being. Ursodeoxycholic acid may also help in normalising the bile acid profile in umbilical cord blood and in amniotic fluid, thus protecting the foetus from the adverse effects of abnormal amounts of bile acids.70
GRAFT-VERSUS-HOST DISEASE
Graft-versus-host disease occurs when an immunocompetent donor T cell recognises the recipient's antigens as foreign, resulting in an immune-mediated injury.71'72 Chronic cholestasis results in up to 80% of patients. 73 The similarity between chronic graft-versus-host disease and primary biliary cirrhosis led to an uncontrolled trial of ursodeoxycholic acid in which 13 patients with chronic refractory graft-versus-host disease were treated with 10-15 mg/kg of ursodeoxycholic acid daily for six weeks. There was symptomatic improvement and biochemical parameters of cholestasis also showed improvement during therapy, although enzyme values returned to pretreatment levels following its discontinuation.73 ACUTE 
